経口タンパク質・ペプチド市場- 世界の産業規模、シェア、動向、機会、予測、薬物タイプ別、用途別、地域別、競合別セグメント、2020-2030F

経口タンパク質・ペプチドの世界市場規模は2024年に13億3,000万米ドルとなり、2030年までの年間平均成長率（CAGR）は9.42％と、予測期間中に大きな成長が見込まれています。

この市場は、製薬およびバイオテクノロジー分野で急速に拡大しています。経口タンパク質およびペプチドは、一般的に錠剤、カプセル剤、液剤の形で経口摂取できる生物活性分子であり、注射療法に代わる治療法を提供します。この投与方法には、患者のコンプライアンス向上、不快感の軽減、ヘルスケアコストの削減など、複数の利点があります。

主な市場促進要因

慢性疾患の増加

主要市場の課題

安定性とバイオアベイラビリティ

主な市場動向：

ナノテクノロジーとドラッグデリバリーシステムの進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の経口タンパク質・ペプチド市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤の種類別（カルシトニン、インスリン、リナクロチド、オクトレオチド、プレカナチド）
  • 用途別（骨疾患、糖尿病、胃・消化器疾患、ホルモン障害）
  • 地域別
  • 企業別（2024）
• 製品市場マップ
  • 薬の種類別
  • 用途別
  • 地域別

第6章 北米の経口タンパク質・ペプチド市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の経口タンパク質・ペプチド市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン

第8章 アジア太平洋地域の経口タンパク質・ペプチド市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国

第9章 南米の経口タンパク質・ペプチド市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの経口タンパク質・ペプチド市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 合併と買収
• 製品上市

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• AbbVie Inc.
• Merck & Co Inc
• Pfizer Inc
• Novo Nordisk A/S
• Hoffmann-La Roche Inc
• Sanofi SA
• AstraZeneca PLC
• Bristol-Myers Squibb Co
• Tarsa Therapeutics Inc
• Novartis AG

第15章 戦略的提言

第16章 調査会社について・免責事項

The Global Oral Proteins & Peptides Market was valued at USD 1.33 billion in 2024 and is expected to experience significant growth during the forecast period, with a compound annual growth rate (CAGR) of 9.42% through 2030. This market is rapidly expanding within the pharmaceutical and biotechnology sectors. Oral proteins and peptides are bioactive molecules that can be taken orally, typically in the form of tablets, capsules, or liquids, providing an alternative to injectable therapies. This method of administration offers multiple advantages, including improved patient compliance, reduced discomfort, and lower healthcare costs.

Key Market Drivers:

Increasing Prevalence of Chronic Diseases

The rising prevalence of chronic diseases is a key factor driving the growth of the oral proteins and peptides market. As the global population ages and lifestyles become more sedentary and unhealthy, the incidence of chronic diseases is increasing. This leads to a larger patient pool that could benefit from oral protein and peptide treatments. According to the World Health Organization, noncommunicable diseases (NCDs) were responsible for 43 million deaths, accounting for 75% of all global deaths unrelated to pandemics. Cardiovascular diseases were the leading cause with 19 million deaths, followed by cancers (10 million), chronic respiratory diseases (4 million), and diabetes (over 2 million). Notably, low- and middle-income countries accounted for 73% of these NCD-related deaths.

Patients with chronic conditions are increasingly seeking convenient treatment options. Many require long-term or lifelong therapies, and traditional methods such as injections or infusions can be burdensome. Oral proteins and peptides provide a more patient-friendly alternative, as they can be taken in the form of a pill or liquid, eliminating the need for painful, frequent injections. Additionally, non-adherence to prescribed treatments is a significant challenge in managing chronic diseases. Oral formulations help address this issue by increasing patient compliance, as treatments that are easier to administer and less intrusive encourage better adherence and lead to improved health outcomes.

Key Market Challenges:

Stability and Bioavailability

A major challenge in the oral administration of proteins and peptides is their susceptibility to degradation in the harsh environment of the gastrointestinal tract. Ensuring their stability and maintaining adequate bioavailability remains a complex issue that requires advanced formulation technologies.

Key Market Trends:

Advancements in Nanotechnology and Drug Delivery Systems

Nanotechnology is transforming drug delivery in the oral proteins and peptides market. Nanoparticles and nanocarriers are being developed to encapsulate and protect these sensitive molecules, enabling more precise delivery and enhanced bioavailability. These innovations are expected to expand the range of treatable diseases and improve therapeutic outcomes.

Key Market Players:

• AbbVie Inc.
• Merck & Co., Inc.
• Pfizer Inc.
• Novo Nordisk A/S
• Hoffmann-La Roche Inc.
• Sanofi S.A.
• AstraZeneca PLC
• Bristol-Myers Squibb Co.
• Tarsa Therapeutics Inc.
• Novartis AG

Report Scope:

This report segments the Global Oral Proteins & Peptides Market into the following categories, with detailed insights into each:

By Drug Type:

• Calcitonin
• Insulin
• Linaclotide
• Octreotide
• Plecanatide

By Application:

• Bone Diseases
• Diabetes
• Gastric & Digestive Disorders
• Hormonal Disorders

By Region:

• North America: United States, Canada, Mexico
• Europe: Germany, United Kingdom, France, Italy, Spain
• Asia-Pacific: China, Japan, India, Australia, South Korea
• South America: Brazil, Argentina, Colombia
• Middle East & Africa: South Africa, Saudi Arabia, UAE, Kuwait

Competitive Landscape and Company Profiles:

This section offers an in-depth analysis of the major players in the Global Oral Proteins & Peptides Market.

Available Customizations:

TechSci Research provides customized reports tailored to specific market needs. The following customization options are available:

• Detailed analysis and profiling of up to five additional market players.

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oral Proteins & Peptides Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Calcitonin, Insulin, Linaclotide, Octreotide, Plecanatide)
  • 5.2.2. By Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders, Hormonal Disorders)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Product Market Map
  • 5.3.1. By Drug Type
  • 5.3.2. By Application
  • 5.3.3. By Region

6. North America Oral Proteins & Peptides Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type (Calcitonin, Insulin, Linaclotide, Octreotide, Plecanatide)
  • 6.2.2. By Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders, Hormonal Disorders)
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Oral Proteins & Peptides Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Oral Proteins & Peptides Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Oral Proteins & Peptides Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Application

7. Europe Oral Proteins & Peptides Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type (Calcitonin, Insulin, Linaclotide, Octreotide, Plecanatide)
  • 7.2.2. By Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders, Hormonal Disorders)
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Oral Proteins & Peptides Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Application
  • 7.3.2. United Kingdom Oral Proteins & Peptides Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Application
  • 7.3.3. France Oral Proteins & Peptides Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Oral Proteins & Peptides Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Oral Proteins & Peptides Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Application

8. Asia-Pacific Oral Proteins & Peptides Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type (Calcitonin, Insulin, Linaclotide, Octreotide, Plecanatide)
  • 8.2.2. By Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders, Hormonal Disorders)
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Oral Proteins & Peptides Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Application
  • 8.3.2. Japan Oral Proteins & Peptides Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Application
  • 8.3.3. India Oral Proteins & Peptides Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Application
  • 8.3.4. Australia Oral Proteins & Peptides Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Application
  • 8.3.5. South Korea Oral Proteins & Peptides Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Application

9. South America Oral Proteins & Peptides Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type (Calcitonin, Insulin, Linaclotide, Octreotide, Plecanatide)
  • 9.2.2. By Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders, Hormonal Disorders)
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Oral Proteins & Peptides Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Oral Proteins & Peptides Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Oral Proteins & Peptides Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Application

10. Middle East and Africa Oral Proteins & Peptides Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type (Calcitonin, Insulin, Linaclotide, Octreotide, Plecanatide)
  • 10.2.2. By Application (Bone Diseases, Diabetes, Gastric & Digestive Disorders, Hormonal Disorders)
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Oral Proteins & Peptides Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Oral Proteins & Peptides Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Oral Proteins & Peptides Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Application
  • 10.3.4. Kuwait Oral Proteins & Peptides Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Drug Type
      • 10.3.4.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. AbbVie Inc.
• 14.2. Merck & Co Inc
• 14.3. Pfizer Inc
• 14.4. Novo Nordisk A/S
• 14.5. Hoffmann-La Roche Inc
• 14.6. Sanofi SA
• 14.7. AstraZeneca PLC
• 14.8. Bristol-Myers Squibb Co
• 14.9. Tarsa Therapeutics Inc
• 14.10.Novartis AG

15. Strategic Recommendations

16. About Us & Disclaimer